Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Total Liabilities data on record, last reported at $558.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 29.5% year-over-year to $558.2 million; the TTM value through Dec 2025 reached $558.2 million, up 29.5%, while the annual FY2025 figure was $558.2 million, 29.5% up from the prior year.
  • Total Liabilities reached $558.2 million in Q4 2025 per MRVI's latest filing, down from $603.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.4 billion in Q3 2021 and bottomed at $429.0 million in Q2 2025.
  • Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.2 billion recorded in 2021.
  • Peak YoY movement for Total Liabilities: plummeted 52.84% in 2024, then grew 29.5% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $1.4 billion in 2021, then increased by 0.3% to $1.4 billion in 2022, then tumbled by 49.34% to $697.6 million in 2023, then crashed by 38.21% to $431.0 million in 2024, then increased by 29.5% to $558.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $558.2 million in Q4 2025, $603.7 million in Q3 2025, and $429.0 million in Q2 2025.